Adaptive Biotechnologies Corp
NASDAQ:ADPT

Watchlist Manager
Adaptive Biotechnologies Corp Logo
Adaptive Biotechnologies Corp
NASDAQ:ADPT
Watchlist
Price: 6.39 USD 6.15%
Market Cap: 943m USD
Have any thoughts about
Adaptive Biotechnologies Corp?
Write Note

Adaptive Biotechnologies Corp
Selling, General & Administrative

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Adaptive Biotechnologies Corp
Selling, General & Administrative Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Selling, General & Administrative CAGR 3Y CAGR 5Y CAGR 10Y
Adaptive Biotechnologies Corp
NASDAQ:ADPT
Selling, General & Administrative
-$160.6m
CAGR 3-Years
-2%
CAGR 5-Years
-21%
CAGR 10-Years
N/A
Thermo Fisher Scientific Inc
NYSE:TMO
Selling, General & Administrative
-$8.5B
CAGR 3-Years
-3%
CAGR 5-Years
-7%
CAGR 10-Years
-7%
Danaher Corp
NYSE:DHR
Selling, General & Administrative
-$6.7B
CAGR 3-Years
5%
CAGR 5-Years
-7%
CAGR 10-Years
-3%
Mettler-Toledo International Inc
NYSE:MTD
Selling, General & Administrative
-$922.4m
CAGR 3-Years
0%
CAGR 5-Years
-3%
CAGR 10-Years
-2%
Agilent Technologies Inc
NYSE:A
Selling, General & Administrative
-$1.5B
CAGR 3-Years
2%
CAGR 5-Years
-1%
CAGR 10-Years
-3%
IQVIA Holdings Inc
NYSE:IQV
Selling, General & Administrative
-$2.1B
CAGR 3-Years
-3%
CAGR 5-Years
-4%
CAGR 10-Years
-9%
No Stocks Found

Adaptive Biotechnologies Corp
Glance View

Market Cap
942.9m USD
Industry
Life Sciences Tools & Services

Adaptive Biotechnologies Corp. engages in the development of an immune medicine platform. The company is headquartered in Seattle, Washington and currently employs 858 full-time employees. The company went IPO on 2019-06-27. The firm is focused on using the biology of the adaptive immune system to develop the diagnosis and treatment of disease. Its immune medicine platform combines a suite of chemistry, biology and machine learning to generate clinical immunomics data to decode the adaptive immune system. Its commercial research products include immunoSEQ and immunoSEQ T-MAP. immunoSEQ utilizes bias-controlled polymerase chain reaction (PCR) to sequence immune receptors from deoxyribonucleic (DNA). Its clonoSEQ diagnostic test detects and monitors the number of cancer cells that are present in a patient’s body during and after treatment, known as minimal residual disease (MRD). The company uses its T cell receptor (TCR)-Antigen Map to develop research solutions and diagnostic products, such as immunoSEQ T-MAP and T-Detect. The company also focuses on developing immune-mediated therapies in oncology and other disease areas.

ADPT Intrinsic Value
6.94 USD
Undervaluation 8%
Intrinsic Value
Price

See Also

What is Adaptive Biotechnologies Corp's Selling, General & Administrative?
Selling, General & Administrative
-160.6m USD

Based on the financial report for Sep 30, 2024, Adaptive Biotechnologies Corp's Selling, General & Administrative amounts to -160.6m USD.

What is Adaptive Biotechnologies Corp's Selling, General & Administrative growth rate?
Selling, General & Administrative CAGR 5Y
-21%

Over the last year, the Selling, General & Administrative growth was 9%. The average annual Selling, General & Administrative growth rates for Adaptive Biotechnologies Corp have been -2% over the past three years , -21% over the past five years .

Back to Top